Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants
- 주제(키워드) SARS-CoV-2 , Measles virus vector , Neutralizing antibody
- 주제(기타) Immunology; Medicine, Research & Experimental
- 설명문(일반) [Kwak, Hye Won; Park, Hyo-Jung; Park, Hyeong-Jun; Nam, Jae-Hwan] Catholic Univ Korea, Dept Med & Biol Sci, Gyeonggi Do, Bucheon, South Korea; [Kwak, Hye Won; Park, Hyo-Jung; Park, Hyeong-Jun; Nam, Jae-Hwan] Catholic Univ Korea, BK Plus Dept Biotechnol, Gyeonggi Do, Bucheon, South Korea; [Kwak, Hye Won; Park, Hyeong-Jun] SML Biopharm, Gyeonggi Do, Bucheon, South Korea; [Jung, Seo-Yeon; Lee, Su Jeen; Seo, Ki-Weon; Lee, Kunse; Kim, Hun] SK Biosci, Dept R&D, Pangyoro, South Korea; [Oh, Eun Young; Kim, Yeonhwa; Park, Sohyun; Lee, Sang-Myeong] Chungbuk Natl Univ, Coll Vet Med, Cheongju 28644, South Korea; [Park, Sang-In; Ko, Hae Li] Scripps Korea Antibody Inst, Div Res Program, Chunchon, Kangwon Do, South Korea; [Kim, You-Jin; Lee, Jung-Ah; Won, Hyeran; Hwang, Yun-Ho; Kim, Seo Yeon; Kim, Se Eun; Kim, Dokeun] Natl Inst Hlth, Natl Inst Infect Dis, Ctr Vaccine Res, Div Infect Dis Vaccine Res, Sejong, South Korea; [Bae, Seoung Eun; Yoon, Minhyuk; Kim, Jae-Ouk; Song, Manki] Int Vaccine Inst, Sci Unit, Seoul 08826, South Korea; [Hong, So-Hee] Ewha Womans Univ, Coll Med, Dept Microbiol, Seoul 07804, South Korea; [Nam, Jae-Hwan] Catholic Univ Korea, Dept Med & Biol Sci, 43-1 Yeokgok Dong, Bucheon 14662, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 ELSEVIER SCI LTD
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000204229
- 본문언어 영어
- Published As https://doi.org/10.1016/j.vaccine.2023.02.005
초록/요약
Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vari-ants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vac-cine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vacci-nation. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the a, b, c, and d variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.(c) 2023 Elsevier Ltd. All rights reserved.
more